Bender, C., Enk, A., & Hassel, J. C. (2016). Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment. Annals of oncology, 27(7), . https://doi.org/10.1093/annonc/mdw128
Chicago-Zitierstil (17. Ausg.)Bender, Carolin, Alexander Enk, und Jessica C. Hassel. "Safety of the PD-1 Antibody Pembrolizumab in Patients with High-grade Adverse Events Under Ipilimumab Treatment." Annals of Oncology 27, no. 7 (2016). https://doi.org/10.1093/annonc/mdw128.
MLA-Zitierstil (9. Ausg.)Bender, Carolin, et al. "Safety of the PD-1 Antibody Pembrolizumab in Patients with High-grade Adverse Events Under Ipilimumab Treatment." Annals of Oncology, vol. 27, no. 7, 2016, https://doi.org/10.1093/annonc/mdw128.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.